vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and i-80 Gold Corp. (IAUX). Click either name above to swap in a different company.
i-80 Gold Corp. is the larger business by last-quarter revenue ($21.3M vs $16.1M, roughly 1.3× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -401.9%, a 394.1% gap on every dollar of revenue.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
i-80 Gold Corp is a mineral exploration and development firm focused on gold and silver asset operations in Nevada, US. It advances high-potential mining projects, using responsible extraction practices to deliver precious metals to global industrial and investment markets.
DERM vs IAUX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $21.3M |
| Net Profit | $-1.2M | $-85.6M |
| Gross Margin | — | 22.0% |
| Operating Margin | -2.8% | -291.6% |
| Net Margin | -7.8% | -401.9% |
| Revenue YoY | 27.3% | — |
| Net Profit YoY | -182.0% | — |
| EPS (diluted) | $-0.04 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $21.3M | ||
| Q3 25 | $17.0M | $32.0M | ||
| Q2 25 | $15.0M | $27.8M | ||
| Q1 25 | $13.1M | $14.0M | ||
| Q4 24 | $12.6M | — | ||
| Q3 24 | $14.6M | $11.5M | ||
| Q2 24 | $14.9M | $7.2M | ||
| Q1 24 | $13.0M | — |
| Q4 25 | $-1.2M | $-85.6M | ||
| Q3 25 | $-2.3M | $-41.9M | ||
| Q2 25 | $-3.8M | $-30.2M | ||
| Q1 25 | $-4.1M | $-41.2M | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $-2.4M | $-43.1M | ||
| Q2 24 | $-3.4M | $-41.0M | ||
| Q1 24 | $-10.4M | — |
| Q4 25 | — | 22.0% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | -42.7% | ||
| Q2 24 | 56.0% | -171.4% | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | -291.6% | ||
| Q3 25 | -9.0% | -86.7% | ||
| Q2 25 | -19.2% | -67.4% | ||
| Q1 25 | -25.3% | -112.3% | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | -19.8% | -210.0% | ||
| Q2 24 | -19.7% | -435.2% | ||
| Q1 24 | -77.4% | — |
| Q4 25 | -7.8% | -401.9% | ||
| Q3 25 | -13.6% | -130.8% | ||
| Q2 25 | -25.3% | -108.5% | ||
| Q1 25 | -31.0% | -293.3% | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | -16.3% | -374.5% | ||
| Q2 24 | -22.6% | -570.8% | ||
| Q1 24 | -80.1% | — |
| Q4 25 | $-0.04 | $-0.10 | ||
| Q3 25 | $-0.09 | $-0.05 | ||
| Q2 25 | $-0.16 | $-0.05 | ||
| Q1 25 | $-0.18 | $-0.10 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $-0.12 | $-0.11 | ||
| Q2 24 | $-0.17 | $-0.11 | ||
| Q1 24 | $-0.53 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $63.2M |
| Total DebtLower is stronger | $25.3M | $174.7M |
| Stockholders' EquityBook value | $31.9M | $346.8M |
| Total Assets | $94.6M | $703.4M |
| Debt / EquityLower = less leverage | 0.79× | 0.50× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $63.2M | ||
| Q3 25 | $24.9M | $102.9M | ||
| Q2 25 | $20.3M | $133.7M | ||
| Q1 25 | $21.1M | $13.5M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | $21.8M | ||
| Q2 24 | $23.9M | $47.8M | ||
| Q1 24 | $24.1M | — |
| Q4 25 | $25.3M | $174.7M | ||
| Q3 25 | $25.2M | $175.9M | ||
| Q2 25 | $25.1M | $175.8M | ||
| Q1 25 | $25.0M | $197.5M | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $346.8M | ||
| Q3 25 | $25.9M | $423.0M | ||
| Q2 25 | $19.2M | $463.5M | ||
| Q1 25 | $21.5M | $318.0M | ||
| Q4 24 | $20.1M | — | ||
| Q3 24 | $10.9M | $346.9M | ||
| Q2 24 | $11.3M | $377.2M | ||
| Q1 24 | $13.0M | — |
| Q4 25 | $94.6M | $703.4M | ||
| Q3 25 | $85.2M | $756.2M | ||
| Q2 25 | $81.2M | $782.9M | ||
| Q1 25 | $85.0M | $659.0M | ||
| Q4 24 | $80.2M | — | ||
| Q3 24 | $64.0M | — | ||
| Q2 24 | $65.2M | — | ||
| Q1 24 | $66.6M | — |
| Q4 25 | 0.79× | 0.50× | ||
| Q3 25 | 0.97× | 0.42× | ||
| Q2 25 | 1.30× | 0.38× | ||
| Q1 25 | 1.16× | 0.62× | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-39.2M |
| FCF MarginFCF / Revenue | — | -184.3% |
| Capex IntensityCapex / Revenue | — | 23.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-93.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-34.3M | ||
| Q3 25 | $-2.4M | $-15.2M | ||
| Q2 25 | $-942.0K | $-11.3M | ||
| Q1 25 | $-2.8M | $-22.7M | ||
| Q4 24 | $2.2M | — | ||
| Q3 24 | $-1.2M | $-23.5M | ||
| Q2 24 | $-5.2M | $-24.6M | ||
| Q1 24 | $-5.0M | — |
| Q4 25 | — | $-39.2M | ||
| Q3 25 | — | $-18.5M | ||
| Q2 25 | — | $-12.4M | ||
| Q1 25 | — | $-23.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-23.8M | ||
| Q2 24 | — | $-25.1M | ||
| Q1 24 | — | — |
| Q4 25 | — | -184.3% | ||
| Q3 25 | — | -57.8% | ||
| Q2 25 | — | -44.7% | ||
| Q1 25 | — | -164.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -206.7% | ||
| Q2 24 | — | -349.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 23.1% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 7.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
IAUX
| Granite Creek Mining Company | $20.3M | 95% |
| Ruby Hill Mining Company LLC | $991.0K | 5% |
| Lone Tree Minning Company | $3.0K | 0% |
